Despite the recent introduction of new therapies for multiple myeloma (MM), it remains an
incurable disease. As MM progresses, patients experience cycles of relapse and remission …

Recent developments in the treatment of multiple myeloma have led to improvements in
response rates and to increased survival; however, relapse is inevitable in almost all …

Despite significant progress in the treatment of multiple myeloma (MM) over the past
decade, this disease remains incurable and almost all patients ultimately experience …

Treatment of relapsed or refractory multiple myeloma (MM) continues to present a
therapeutic challenge. The immunomodulatory drugs (IMiDs) thalidomide and lenalidomide …

The practice of choosing the next best therapy for patients with relapsed and/or refractory
multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus …

A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become
available, extending progression-free and overall survival for patients in meaningful ways …

Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

In the last decade, the introduction of novel agents including the immunomodulatory drugs
thalidomide and lenalidomide, and the first-in-class proteasome inhibitor bortezomib, has …

Multiple classes of agent with distinct mechanisms of action are now available for the
treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including …

In spite of significant advances in the management of multiple myeloma (MM), the disease
remains incurable and nearly all patients ultimately relapse and require salvage …